- ►marchwellness.net [PDF] D Grimm, MA Kay - Current Gene Therapy, 2003 - ingentaconnect.com Abstract: Gene transfer vectors based on the human adeno-associated virus serotype 2
(AAV-2) have been developed and tested in pre-clinical studies for almost 20 years, and are
currently being evaluated in clinical trials. So far, all these studies have provided ... Cited by 168 - Related articles - BL Direct - All 9 versions
- ►pnas.org K Goudy, S Song, C Wasserfall, YC … - Proceedings of the …, 2001 - National Acad Sciences The development of spontaneous autoimmune diabetes in nonobese diabetic (NOD) mice provides
for their use as a model of human type 1 diabetes. To test the feasibility of muscle-directed gene
therapy to prevent type 1 diabetes, we developed recombinant adeno-associated virus ( ... Cited by 92 - Related articles - BL Direct - All 12 versions
- ►jimmunol.org Z Yang, M Chen, R Wu, LB Fialkow, JS … - The Journal of …, 2002 - Am Assoc Immnol Th1 cell activation and cytokine production shift the balance between Th1 and Th2, favoring
the up-regulation of proinflammatory activity that leads to destruction of insulin-producing pancreatic
cells in type 1 diabetes. Th2-type cytokines, such as IL-10, have immune regulatory ... Cited by 78 - Related articles - BL Direct - All 4 versions
- ►ufl.edu [PDF] KH Warrington, RW Herzog - Human genetics, 2006 - Springer Abstract During the past decade, in vivo administration of viral gene transfer vectors for treatment
of numerous human diseases has been brought from bench to bedside in the form of clinical
trials, mostly aimed at establishing the safety of the protocol. In preclinical studies in ... Cited by 68 - Related articles - BL Direct - All 4 versions
SA Loiler, TJ Conlon, S Song, Q Tang, KH Warrington, … - Gene Therapy, 2003 - nature.com Human pancreatic islet cells and hepatocytes represent the two most likely target cells for genetic
therapy of type I diabetes. However, limits to the efficiency of rAAV serotype 2 (rAAV2)-mediated
gene transfer have been reported for both of these cell targets. Here we report that ... Cited by 65 - Related articles - BL Direct - All 3 versions
M Fowler, J Virostko, Z Chen, G Poffenberger, A … - Transplantation, 2005 - journals.lww.com Fowler, Michael; Virostko, John; Chen, Zhongyi; Poffenberger, Greg; Radhika, Aramandla;
Brissova, Marcela; Shiota, Masakazu; Nicholson, Wendell E.; Shi, Yubin; Hirshberg, Boaz;
Harlan, David M.; Jansen, E Duco; Powers, Alvin C. ... 1 Department of Medicine, ... Cited by 45 - Related articles - All 7 versions
R Bottino, P Lemarchand, M Trucco, N Giannoukakis - Gene Therapy, 2003 - nature.com Type 1 diabetes mellitus, an autoimmune disorder is an attractive candidate for gene and
cell-based therapy. From the use of gene-engineered immune cells to induce hyporesponsiveness
to autoantigens to islet and beta cell surrogate transplants expressing immunoregulatory ... Cited by 44 - Related articles - BL Direct - All 4 versions
- ►endocrinology-journals.org SK Richards, LE Parton, I Leclerc, GA Rutter, … - Journal of …, 2005 - Soc Endocrinology Treatment of type 1 diabetes by islet transplantation is currently limited by loss of functional
ß-cell mass after transplantation. We investigated here whether adenovirus-mediated changes
in AMP-activated protein kinase (AMPK) activity, previously shown to affect insulin ... Cited by 45 - Related articles - BL Direct - All 6 versions
- ►pnas.org S Chen, J Ding, R Bekeredjian, B Yang, … - Proceedings of the …, 2006 - National Acad Sciences This study describes a method of gene delivery to pancreatic islets of adult, living animals by
ultrasound targeted microbubble destruction (UTMD). The technique involves incorporation of
plasmids into the phospholipid shell of gas-filled microbubbles, which are then infused ... Cited by 41 - Related articles - BL Direct - All 9 versions
